Arcutis Biotherapeutics, Inc. (ARQT) Financial Statements
Arcutis Biotherapeutics, Inc. (ARQT) reported trailing twelve-month revenue of $464.0M (up 76.1% year on year) and net income of $28.5M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $39.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ARQTArcutis Biotherapeutics, Inc.Follow ARQT — free
—
Price chart with a free account
- Market cap
- 3.9B
- P/E TTM
- 148.6
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Revenue | 3.7 | 59.6 | 196.5 | 376.1 | 464.0 | |
| Gross profit | — | 54.6 | 177.4 | 339.4 | 422.9 | |
| Research & development | 182.4 | 110.6 | 76.4 | 77.1 | 91.0 | |
| Operating income | -301.6 | -241.1 | -128.4 | -12.2 | 34.3 | |
| Pre-tax income | -311.5 | -259.0 | -139.4 | -15.0 | 29.3 | |
| Income tax | 0.0 | 3.1 | 0.6 | 1.2 | 0.8 | |
| Net income | -311.5 | -262.1 | -140.0 | -16.1 | 28.5 | |
| Diluted EPS ($) | -5.66 | -3.78 | -1.16 | -0.13 | 0.21 | |
| Diluted shares (mn) | 55.0 | 69.3 | 121.0 | 127.2 | — |
USD millions · SEC XBRL
Arcutis Biotherapeutics, Inc. — questions
- What is Arcutis Biotherapeutics, Inc.'s revenue?
- $464.0M over the twelve months to 2026-06-30, up 76.1% year on year, from its 10-Q and 10-K filings.
- What is Arcutis Biotherapeutics, Inc.'s net income?
- $28.5M over the twelve months to 2026-06-30.
- What is Arcutis Biotherapeutics, Inc.'s free cash flow?
- $39.2M over the twelve months to 2026-06-30.
- What are Arcutis Biotherapeutics, Inc.'s diluted earnings per share?
- $0.21 over the twelve months to 2026-06-30.
Every figure on this page comes from Arcutis Biotherapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.